StephenPaulSallowayMD

Director of Neurology and the Memory and Aging Program at Butler Hospital in Providence, Rhode Island, and Professor of Clinical Neurosciences and Psychiatry at Brown Medical School. He is the Director of the Brown Combined Residency in Neurology and Psychiatry and Codirector of the National Institute on Aging-sponsored Brown Dementia Research Fellowship Program

Join to view full profile

Are you Dr. Salloway?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 69 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
345 Blackstone Blvd
Providence, RI 02906
Phone+1 401-455-6200

Fax+1 401-455-6309

Summary

Dr. Stephen Salloway, MD is a board certified neurologist in Providence, Rhode Island. He is currently licensed to practice medicine in Rhode Island. He is affiliated with Butler Hospital, Rhode Island Hospital, and Women & Infants Hospital of Rhode Island.

Education & Training

Yale-New Haven Medical CenterResidency, Neurology, 1988 - 1991
Yale-New Haven Medical CenterResidency, Psychiatry, 1985 - 1988
Stanford University School of MedicineClass of 1985

Certifications & Licensure

RI State Medical License 1991 - 2026
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Dominantly Inherited Alzheimer Network (DIAN) Start of enrollment: 2009 Jan 01
Recruiting
Clinical Evaluation of Florbetapir F 18 (18F-AV-45) Start of enrollment: 2009 Dec 01
Completed
Phase 2
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo Start of enrollment: 2013 Jul 01
Terminated
Phase 3
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss Start of enrollment: 2014 Feb 28
Completed
Phase 3
Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects Start of enrollment: 2013 Dec 01
Completed
Phase 2, Phase 3
18F-AV-1451 Autopsy Study Start of enrollment: 2015 Sep 01
Completed
Phase 3
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease Start of enrollment: 2016 Jun 01
Terminated
Phase 3
Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD Start of enrollment: 2021 Dec 17
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

606 citations
Donanemab in Early Alzheimer's Disease.
Mark A Mintun, Albert C. Lo, Cynthia Duggan Evans, Alette M. Wessels, Paul A. Ardayfio
The New England Journal of Medicine. 2021-03-13
2486 citations
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer’s Disease
Randall J. Bateman, Chengjie Xiong, Tammie L.S. Benzinger, Anne M. Fagan, Alison Goate
The New England Journal of Medicine. 2012-08-29
228 citations
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease.
Oskar Hansson, Rebecca M Edelmayer, Adam L Boxer, Maria C Carrillo, Michelle M Mielke
Alzheimer's & Dementia. 2022-12-01

Press Mentions

Ozempic Linked to Lower Alzheimer's Risk in People with Type 2 DiabetesOctober 24th, 2024
Alzheimer's Blood Test More Accurate Than Primary Care or Specialist DiagnosesJuly 28th, 2024
Israeli Attacks Kill at Least 19 Palestinians, Including Children, Across GazaJuly 28th, 2024
Join now to see all

Grant Support

Aging Brain: DTI, Subcortical Ischemia And BehavioralNational Institute On Aging2005–2006
Subcortical Microvascular Disease In DepressionNational Institute Of Mental Health1999–2003